… associated with treating genital warts in the USA among a commercially insured population.
… -year costs associated with treating genital warts in the USA among a commercially insured …

… care and reducing population-level costs. This study is limited by its restriction to a commercially
insured population and an inability to assess relative effectiveness of wart treatments. …

… . Assessing incidence and economic burden of genital warts with data from a US
commercially insured population. Curr Med Res Opin 2009;25:2343–51.doi:10.1185/…

… This study provides the first quantification of the economic burden of treating genital warts
in Peru and one of the few in Latin America. The costing data did not include other healthcare …

… utilization of GW within the Russian population, it can be generally … US commercially insured
population reported estimated costs at $760 per 1000 individuals in the general population …

… This study estimated genital warts prevalence, genital-warts-related healthcare resource
use and costs, and self-reported human-papillomavirus-related psychosocial impact among …

… One such disease concerns the highly infectious and one of the most 5 common viral
sexually transmissible diseases worldwide: genital warts (GW; condylomata 6 accuminata). 7 …

… the prevalence of genital warts in Taiwan among those seeking healthcare, as well as
genital-warts-related healthcare resource use and costs, and self-reported genital-warts-related …

… The present review attempts to provide an overview of all treatments for genital warts
currently available and to translate the significance/usefulness of novel treatment options into a …

… HPV-6 and HPV-11 accounted for approximately 90% of anogenital warts (AGWs), while
HPV-16 and HPV-18 accounted for … HPV is also associated with other anogenital cancers (…